North America Led the Anti-Biofilm Wound Dressing Market

As per a report by P&S Intelligence, the anti-biofilm wound dressing market generated a value of USD 730 million in 2022, and it will grow at an 8.9% CAGR, to touch USD 1,447 million, by 2030.

To learn more about this report: https://bit.ly/3pDT1SR

The growth in the industry is mainly attributed to the increasing consumption of alcohol & tobacco and sedentary & unhealthy lifestyles, which lead to the growing incidence of chronic diseases, therefore, increasing the incidence rate of chronic and acute lesions, along with the rising antimicrobial resistance threat, boosts the requirement for these products.

The chemical category accounted for the largest anti-biofilm wound dressing market revenue share, at approximately 46%, owing to the rising number of surgeries and increasing chronic wound incidence all over the world.

North America led the industry of anti-biofilm wound dressing, and it will maintain its position in the years to come, generating a value of USD 434 million, by the end of this decade. This is ascribed to the increasing incidence of sports injuries and the growing number of road accidents.

Additionally, the U.S. led the industry in North America, and it will advance at a rate of approximately 9%. This is credited to the strong infrastructure of healthcare and the existence of numerous major industry players. Furthermore, the presence of advantageous reimbursement policies will boost the industry's growth in the years to come.

Hence, with the increasing prevalence of chronic wounds and the mounting number of accidents, violence, and burns cases, the industry of anti-biofilm wound dressing will continue to grow significantly in the years to come.

Read More

High-Throughput Screening Market is Expected to Witness the Fastest Growth in APAC During the Forecast Period

The global high-throughput screening market size is witnessing considerable growth due to increasing geriatric population, increasing healthcare expenditure, increasing research and development activities, launch of technologically advanced products that are miniaturized and automated and growing popularity of high-throughput screening for drug discovery. Moreover, high adoption of high-throughput screening models in pharmaceutical and biotechnology companies across the globe is supporting the growth of the market. Based on technology, 2D cell culture segment is expected to grow at the fastest rate during the forecast period owing to its low cost and ease of use.

The rapid growth in emerging economies and growing research and development activities on stem cells and toxicology is expected to create opportunities for the manufacturers of high-throughput screening products. However, high cost of high-throughput screening, lack of trained professionals and complexity in assay development are the key factors hampering the growth of the global market.

To Learn More About this report at: http://bit.ly/34YdFwQ

Geographically, North America has been the largest market for high-throughput screening, owing to its increased awareness, increasing government funding, established healthcare industry, and easy accessibility to advanced technologies due to the awareness in the region. The U.S. contributed largest revenue to the North American as well as global high-throughput screening market. The increased research and development activities and increasing prevalence of chronic diseases arising the need for novel treatments is the key growth driving factor for the U.S. high-throughput screening market.

Globally, the high-throughput screening market is expected to witness the fastest growth in Asia-Pacific during the forecast period. The highest growth in the region is attributed to the increasing research and development activities, increasing per capita income leading to improving standard of living, increasing healthcare spending, growing demand for better quality medical care, and awareness about high-throughput screening in the region.

The key players operating in the global market are Agilent Technologies, Inc, Danaher Corporation, Thermo Fisher Scientific Inc., Merck Millipore, Bio-Rad Laboratories, Inc., Hamilton Company and Aurora Biomed, Inc.

Read More